<DOC>
	<DOCNO>NCT02348255</DOCNO>
	<brief_summary>This phase II trial study safety NovoTTF-100A combination bevacizumab carmustine see well work treat patient glioblastoma multiforme return first time . NovoTTF-100A , type electric field therapy , delivers low intensity , alternate `` wave-like '' electric field may interfere multiplication glioblastoma multiforme cell . Monoclonal antibody , bevacizumab , may interfere ability tumor cell grow spread . Drugs use chemotherapy , carmustine , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving NovoTTF-100A together bevacizumab carmustine may effective treatment glioblastoma multiforme .</brief_summary>
	<brief_title>NovoTTF-100A With Bevacizumab Carmustine Treating Patients With Glioblastoma Multiforme First Relapse</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish safety NovoTTF-100A combination bevacizumab BCNU ( carmustine ) glioblastoma multiforme ( GBM ) patient relapse chemoradiation therapy ( first relapse ) . II . Determine 6 month overall survival ( OS ) . III . Determine 6 month progression free survival ( PFS ) . IV . Evaluate effect therapy regimen quality-of-life . OUTLINE : Patients receive bevacizumab intravenously ( IV ) 30-90 minute every 2 week begin day -7 13 dos carmustine IV 4 hour every 8 week begin day 1 3 dos . Patients also undergo NovoTTF-100A accord standard procedure start one week first dose carmustine . After completion study treatment , patient follow 12 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Histologically confirm GBM Progressive disease temozolomide radiation therapy ( `` first relapse '' ) At least 28 day since chemotherapy radiation Karnofsky performance score least 70 % Platelet count &gt; = 130/mm^3 Absolute neutrophil count &gt; = 1500/mm^3 Calculated creatinine clearance great 45 mg/dl use CockcroftGault formula Aspartate aminotransferase ( AST ) &lt; 2 time upper limit normal Bilirubin &lt; 1.5 time upper limit normal Subjects childbearing potential agree use effective mean contraception Prior systemically administer nitrosoureas vascular endothelial growth factor ( VEGF ) target therapy Chemotherapy glioma temozolomide Gliadel wafer ( steroid allow ) Pregnant breast feed Active inflammatory bowel disease Abdominal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within 6 month Hypertension : systolic blood pressure ( SBP ) &gt; 150 diastolic blood pressure ( DBP ) &gt; 100 mm mercury ( Hg ) despite antihypertensive medication New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) ; myocardial infarction unstable angina within 6 month History thrombosis Symptomatic peripheral vascular disease , stroke transient ischemic attack within 6 month Bleeding risk : Required therapeutic anticoagulation ( aspirin allow ) , coagulopathy ( e.g . hemophilia von Willebrand 's disease ) ; grade III great hemorrhage , major surgical procedure , significant trauma within 28 day ; core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day Activated partial thromboplastin time ( APTT ) must exceed 32.5 second ( normal range 21.831.5 second ) ; international normalize ratio ( INR ) must exceed 1.30 ( normal range 0.871.18 ) Serious , nonhealing wound , ulcer , bone fracture Active implant medical device ( e.g . deep brain stimulators , spinal cord stimulators , vagus nerve stimulators , pacemaker , defibrillator , programmable shunt ) , skull defect ( miss bone replacement ) , shunt , bullet fragment Known sensitivity conductive hydrogel like gel use electrocardiogram ( ECG ) stickers transcutaneous electrical nerve stimulation ( TENS ) electrodes Human immunodeficiency virus ( HIV ) positive Proteinuria screening demonstrate urine dipstick &gt; = 2+ Prior organ transplantation Known hypersensitivity Chinese hamster ovary cell product recombinant human antibody Aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ) , clopidogrel drug whose goal inhibit platelet function Unable give sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>